Compare Lululemon Athletica Inc (LULU) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lululemon Athletica Inc vs Organon & Co. Common Stock — how do they compare? Lululemon Athletica Inc trades at $93.58 (market cap $10.44B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Lululemon Athletica Inc is far larger — about 2.9× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Lululemon Athletica Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lululemon Athletica Inc for 106 Days and Organon & Co. Common Stock for 0 Days on average.
| LULU | OGN | |
|---|---|---|
Market Cap | $10.44B | $3.62B |
Volume | 2,759,135 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $215.88 | $13.81 |
52-Week Low | $91.88 | $5.70 |
Typical Hold Time | 106 Days | 0 Days |
Enterprise Value | $11.20B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lululemon stock trades at $94.09, down 54% year-to-date and near its 52-week low. The technical picture is bearish with resistance at $96 and support at $93. Fundamentally, the company reported strong revenue of $10.59B in 2025 and a net income margin of 12.78%, but faces growth concerns. Recent news highlights a securities fraud investigation and competitive pressures in athletic apparel.
The outlook is cautious due to legal overhangs and weakening sentiment, though valuation ratios like a P/E of 7.76 appear attractive. Risks include governance turmoil and consumer shifts. Analyst consensus is a $97.67 price target with a mixed buy/hold rating split, suggesting potential recovery if execution improves.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
